| Author |
Median radiation dose (range) |
Frequently used radiation doses and fractions |
Resection |
Chemotherapy |
Grade3 or higher toxicity |
Local control |
Median survival time |
| Takahashi et al [13]. |
50 Gy (5-60) |
50 Gy in three times weekly fractions of 5 Gy |
26% |
42%, concurrent |
Skin toxicity (Grade3; 5%), Dysphagia (Grade3; 26%), Esophagitis (Grade3; 5%), Trachea necrosis (Grade4; 5%) |
74% (at the time of death) |
3.4 months |
| Takahashi et al [13]. |
55.5 Gy (6-70) |
60 Gy in a daily fraction of 2-3 Gy |
50% |
50%, concurrent |
Skin toxicity (Grade3; 7%), Dysphagia (Grade3; 36%), Esophagitis (Grade3; 14%) |
50% |
5.2 months |
| Dumke et al [14]. |
50 Gy (6–60.4) |
Single dose is unknown. Daily (87.5%), every other day (5%), twice daily (5%). |
80% |
15% |
Skin toxicity (Grade3; 13%), Dysphagia (Grade3; 25%, Grade4; 3%) |
Unknown |
5 months |
| Dandekar et al [15]. |
57 Gy (7.6-60.8) |
60.8 Gy in twice daily fractions of 1.8 and 2 Gy |
32% |
Unknown |
Erythema (Grade3; 38%, Grade4; 18%), Desquamation (Grade3; 12%, Grade4; 9%), Dysphagia (Grade3; 30%, Grade4; 44%), Esophagitis (Grade3; 30%, Grade4; 47%) |
85% (at the time of death or last follow up) |
70 days |
| Stavas et al [16]. |
54 Gy (40-62.5) |
54 Gy in a daily fraction of 3Gy |
89% |
88%, concurrent |
Skin toxicity (Grade3; 24%), Dysphagia (Grade3; 28%), Esophagitis (Grade3; 18%) |
82% (at the time of death) |
9.3 months |
| Jingu et al [17]. |
50 Gy (40-50) |
50 Gy in three times weekly fractions of 5 Gy |
Unknown |
50% |
Unknown |
90% (1 year) |
About 3 months |
